Skip to main content

Advertisement

Log in

Novel Pathogenic C5 Gene Variants in a Patient with Neisseria Meningitis and Diffuse Cutaneous HSV-1 Infection

  • Letter to Editor
  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Data Availability

Not applicable as this is a case report without a data repository. All PHI was protected with HIPAA-regulated guidelines, and author communication was completed in HIPAA-secure communication avenues.

References

  1. Wen L, et al. Clinical and laboratory evaluation of complement deficiency. J Allergy Clin Immunol. 2004;113(4):585.

    Article  PubMed  CAS  Google Scholar 

  2. Franco-Jarava C, Comas D, Orren A, Hernández-González M, Colobran R. Complement factor 5 (C5) p.A252T mutation is prevalent in, but not restricted to, sub-Saharan Africa: implications for the susceptibility to meningococcal disease. Clin Exp Immunol. 2017;189(2):226–31.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Owen EP, Würzner R, Leisegang F, Rizkallah P, Whitelaw A, Simpson J, Thomas AD, Harris CL, Giles JL, Hellerud BC, Mollnes TE, Morgan BP, Potter PC, Orren A. A complement C5 gene mutation, c.754G>A:p.A252T, is common in the Western Cape, South Africa and found to be homozygous in seven percent of Black African meningococcal disease cases. Mol Immunol. 2015;64(1):170–6.

    Article  PubMed  CAS  Google Scholar 

  4. Wang X, Fleischer DT, Whitehead WT, Haviland DL, Rosenfeld SI, Leddy JP, Snyderman R, Wetsel RA. Inherited human complement C5 deficiency. Nonsense mutations in exons 1 (Gln1 to Stop) and 36 (Arg1458 to Stop) and compound heterozygosity in three African-American families. J Immunol. 1995;154(10):5464–71.

    Article  PubMed  CAS  Google Scholar 

  5. Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O’Brien F, Wang JJ, Mantegazza R, REGAIN Study Group. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976–86.

    Article  PubMed  CAS  Google Scholar 

  6. Hillmen P, Muus P, Dührsen U, Risitano AM, Schubert J, Luzzatto L, Schrezenmeier H, Szer J, Brodsky RA, Hill A, Socié G, Bessler M, Rollins SA, Bell L, Rother RP, Young NS. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110(12):4123–8.

    Article  PubMed  CAS  Google Scholar 

  7. Verzosa AL, McGeever LA, Bhark SJ, Delgado T, Salazar N, Sanchez EL. Herpes simplex virus 1 infection of neuronal and non-neuronal cells elicits specific innate immune responses and immune evasion mechanisms. Front Immunol. 2021;31(12): 644664.

    Article  Google Scholar 

Download references

Funding

No funding was obtained for this study.

Author information

Authors and Affiliations

Authors

Contributions

Dr. W. GD: Primary author, editing, completed literature review, coordination.

Dr. Luke Pittman: Physician who cared for case patient while in the hospital and follow-up with him afterwards. Assisted with writing, edits.

Dr. Christian Horn: Helped write, edit, proofread article, senior resident of medicine team taking care of case patient while he was in the hospital.

Dr. Jacob Hogue: Geneticist who obtained genetic testing for case patient and reported the specific mutations. Wrote and edited portions of article regarding the patient’s mutations.

Dr. Jared Magee: Helped write, edit, and proofread article.

Dr. Shahrooz Shayegan: Allergist in consultation regarding case patient; followed-up with patient, recommended specific testing for immunodeficiency, helped write, edit, proofread article.

Corresponding author

Correspondence to W. Grant Day.

Ethics declarations

Ethics Approval/Consent to Participate

The patient consented to participate in this report to include laboratory and genetic testing.

Conflict of Interest

All the authors involved in the project declare there are no conflict of interests.

Competing Interests

None of the authors involved in the production of this article have any competing interests to report.

Disclaimer

The views expressed in this article are those of the author(s) and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, or the US Government.

Copyright Statement

Authors are US military service members. This work was prepared as part of their official duties. Title 17 U.S.C. 105 provides that “Copyright protection under this title is not available for any work of the United States Government.” Title 17 U.S.C. 101 defines United States Government work as a work prepared by a military service member as part of that person’s official duties.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Day, W.G., Horn, C., Hogue, J.S. et al. Novel Pathogenic C5 Gene Variants in a Patient with Neisseria Meningitis and Diffuse Cutaneous HSV-1 Infection. J Clin Immunol 44, 52 (2024). https://doi.org/10.1007/s10875-024-01651-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10875-024-01651-7

Navigation